Respiratory Syncytial Virus (RSV) has long been a global public health focus, representing a significant unmet medical need that could benefit from the immunization of infants, pregnant women, and seniors. This past year the United States saw one of the most severe and early RSV seasons in history. The industry has been leveraging partnerships with academia and government to bring novel approaches to help solve this growing public health crisis. This distinguished panel of industry experts will showcase the various technologies that could have a powerful impact on our ability to control the risk of RSV across all ages. Panelists will share information on new vaccines and monoclonal antibodies that are in development and review for approval and recommendations by the FDA and CDC. In addition, panelists will discuss the most important implementation issues that must be managed to best ensure broad access to these immunizations for all eligible populations.